Clinical Trial Update: Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F) [Phase 2]

View source ↗

Summary

Phase 2 MATCH subprotocol F study evaluating crizotinib for cancers with ALK genetic changes. The trial is currently active but not recruiting, with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Malignant Solid Neoplasm
• Multiple Myeloma

Drugs mentioned

• Xalkori (crizotinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-09-22